Sixty milligram daclatasvir is the right dose for hepatitis C virus treatment in combination with etravirine and darunavir/ritonavir

Smolders, Elise J; Kanter, Clara T. M. M. de; Grintjes, Karin; D’Avolio, Antonio; Perri, Giovanni Di; Crevel, Reinout van; Drenth, Joost P.H.; Burger, David M.

doi:10.1097/qad.0000000000001089

Search citation statements

Order By: Relevance

Paper Sections

Select...

Dolutegravir Is Not Removed During Hemodialysis1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2016

2019

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is analogous to the interaction between maraviroc (CYP3A4 substrate), efavirenz (CYP3A4 inducer), and protease inhibitors (CYP3A4 inhibitors). Boosted protease inhibitors mitigated the inducing effect of efavirenz on maraviroc, and hence the dose of maraviroc should be based on the presence of the boosted protease inhibitor [13]. Based on the pharmacokinetic parameters and the achievement of SVR12, we believe that the exposure to daclatasvir was adequate.…”

Section: Dolutegravir Is Not Removed During Hemodialysismentioning

confidence: 99%